Literature DB >> 10482608

Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model.

Y J Hernandez1, J Wang, W G Kearns, S Loiler, A Poirier, T R Flotte.   

Abstract

Latent infection with wild-type (wt) adeno-associated virus (AAV) was studied in rhesus macaques, a species that is a natural host for AAV and that has some homology to humans with respect to the preferred locus for wt AAV integration. Each of eight animals was infected with an inoculum of 10(10) IU of wt AAV, administered by either the intranasal, intramuscular, or intravenous route. Two additional animals were infected intranasally with wt AAV and a helper adenovirus (Ad), while one additional animal was inoculated with saline intranasally as a control. There were no detectable clinical or histopathologic responses to wt AAV administration. Molecular analyses, including Southern blot, PCR, and fluorescence in situ hybridization, were performed 21 days after infection. These studies indicated that AAV DNA sequences persisted at the sites of administration, albeit at low copy number, and in peripheral blood mononuclear cells. Site-specific integration into the AAVS1-like locus was observed in a subset of animals. All animals, except those infected by the intranasal route with wt AAV alone, developed a humoral immune response to wt AAV capsid proteins, as evidenced by a >/=fourfold rise in anti-AAV neutralizing titers. However, only animals infected with both wt AAV and Ad developed cell-mediated immune responses to AAV capsid proteins. These findings provide some insights into the nature of anti-AAV immune responses that may be useful in interpreting results of future AAV-based gene transfer studies.

Entities:  

Mesh:

Year:  1999        PMID: 10482608      PMCID: PMC112875          DOI: 10.1128/JVI.73.10.8549-8558.1999

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

Review 1.  Parvovirus replication.

Authors:  K I Berns
Journal:  Microbiol Rev       Date:  1990-09

2.  Site-specific integration by adeno-associated virus.

Authors:  R M Kotin; M Siniscalco; R J Samulski; X D Zhu; L Hunter; C A Laughlin; S McLaughlin; N Muzyczka; M Rocchi; K I Berns
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

3.  Organization of adeno-associated virus DNA in latently infected Detroit 6 cells.

Authors:  R M Kotin; K I Berns
Journal:  Virology       Date:  1989-06       Impact factor: 3.616

4.  Integration of the adeno-associated virus genome into cellular DNA in latently infected human Detroit 6 cells.

Authors:  A K Cheung; M D Hoggan; W W Hauswirth; K I Berns
Journal:  J Virol       Date:  1980-02       Impact factor: 5.103

5.  Mapping and direct visualization of a region-specific viral DNA integration site on chromosome 19q13-qter.

Authors:  R M Kotin; J C Menninger; D C Ward; K I Berns
Journal:  Genomics       Date:  1991-07       Impact factor: 5.736

6.  Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector.

Authors:  T R Flotte; S A Afione; C Conrad; S A McGrath; R Solow; H Oka; P L Zeitlin; W B Guggino; B J Carter
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-15       Impact factor: 11.205

7.  Detection of adeno-associated virus type 2 in human peripheral blood cells.

Authors:  Z Grossman; E Mendelson; F Brok-Simoni; F Mileguir; Y Leitner; G Rechavi; B Ramot
Journal:  J Gen Virol       Date:  1992-04       Impact factor: 3.891

8.  A seroepidemiologic study of adenovirus-associated virus infection in infants and children.

Authors:  N R Blacklow; M D Hoggan; M S Sereno; C D Brandt; H W Kim; R H Parrott; R M Chanock
Journal:  Am J Epidemiol       Date:  1971-10       Impact factor: 4.897

9.  Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination.

Authors:  R M Kotin; R M Linden; K I Berns
Journal:  EMBO J       Date:  1992-12       Impact factor: 11.598

10.  Targeted integration of adeno-associated virus (AAV) into human chromosome 19.

Authors:  R J Samulski; X Zhu; X Xiao; J D Brook; D E Housman; N Epstein; L A Hunter
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

View more
  51 in total

1.  Ribozyme rescue of photoreceptor cells in P23H transgenic rats: long-term survival and late-stage therapy.

Authors:  M M LaVail; D Yasumura; M T Matthes; K A Drenser; J G Flannery; A S Lewin; W W Hauswirth
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

2.  Genetic fate of recombinant adeno-associated virus vector genomes in muscle.

Authors:  Bruce C Schnepp; K Reed Clark; Dori L Klemanski; Christina A Pacak; Philip R Johnson
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

3.  Adeno-associated viruses undergo substantial evolution in primates during natural infections.

Authors:  Guangping Gao; Mauricio R Alvira; Suryanarayan Somanathan; You Lu; Luk H Vandenberghe; John J Rux; Roberto Calcedo; Julio Sanmiguel; Zahra Abbas; James M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-25       Impact factor: 11.205

4.  Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain.

Authors:  Mihail Y Mastakov; Kristin Baer; C Wymond Symes; Claudia B Leichtlein; Robert M Kotin; Matthew J During
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

5.  Examining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-associated virus serotypes 1 and 5.

Authors:  Carole E Harbison; Wendy S Weichert; Brittney L Gurda; John A Chiorini; Mavis Agbandje-McKenna; Colin R Parrish
Journal:  J Gen Virol       Date:  2011-11-09       Impact factor: 3.891

Review 6.  Safe harbours for the integration of new DNA in the human genome.

Authors:  Michel Sadelain; Eirini P Papapetrou; Frederic D Bushman
Journal:  Nat Rev Cancer       Date:  2011-12-01       Impact factor: 60.716

7.  Structure of adeno-associated virus-2 in complex with neutralizing monoclonal antibody A20.

Authors:  Dustin M McCraw; Jason K O'Donnell; Kenneth A Taylor; Scott M Stagg; Michael S Chapman
Journal:  Virology       Date:  2012-06-09       Impact factor: 3.616

8.  Striatal readministration of rAAV vectors reveals an immune response against AAV2 capsids that can be circumvented.

Authors:  Carmen S Peden; Fredric P Manfredsson; Sharon K Reimsnider; Amy E Poirier; Corinna Burger; Nicholas Muzyczka; Ronald J Mandel
Journal:  Mol Ther       Date:  2009-01-13       Impact factor: 11.454

9.  Cardiac-selective expression of extracellular superoxide dismutase after systemic injection of adeno-associated virus 9 protects the heart against post-myocardial infarction left ventricular remodeling.

Authors:  Prasad R Konkalmatt; Ronald J Beyers; Daniel M O'Connor; Yaqin Xu; Marc E Seaman; Brent A French
Journal:  Circ Cardiovasc Imaging       Date:  2013-03-27       Impact factor: 7.792

10.  Adeno-associated virus serotype 9 administered systemically after reperfusion preferentially targets cardiomyocytes in the infarct border zone with pharmacodynamics suitable for the attenuation of left ventricular remodeling.

Authors:  Prasad R Konkalmatt; Feng Wang; Bryan A Piras; Yaqin Xu; Daniel M O'Connor; Ronald J Beyers; Frederick H Epstein; Brian H Annex; John A Hossack; Brent A French
Journal:  J Gene Med       Date:  2012 Sep-Oct       Impact factor: 4.565

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.